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Abstract
Background: Health-related quality of life (HRQL) is impaired in patients with idiopathic pulmonary fibrosis (IPF).
The King’s Brief Interstitial Lung Disease questionnaire (K-BILD) is a validated measure of HRQL, but no previous
studies have focused on the validity of K-BILD in IPF. Moreover, the relationship between K-BILD and dyspnoea or
the 6-min walk test (6MWT) has not been assessed. The aim of this study was to validate K-BILD in the largest
cohort of patients with IPF to date and assess how K-BILD correlates to dyspnoea and 6MWT.
Methods: Firstly, K-BILD was translated into Danish using validated translation procedures. Consecutive patients
with IPF were recruited. At baseline, patients completed K-BILD, the IPF-specific version of St. Georges Respiratory
Questionnaire, University of California, San Diego Shortness of Breath Questionnaire (SOBQ) Short Form-36, and
pulmonary function tests and 6MWT were performed. After 14 days, K-BILD and Global Rating of Change Scales
were completed. Internal consistency, concurrent validity, test-retest reliability and known groups validity were
assessed. Analyses were also performed in subgroups of patients with different time since diagnosis.
Results: At baseline, 150 patients with IPF completed the questionnaires, and 139 patients completed the
questionnaires after 14 days. K-BILD had a high internal consistency (Cronbach’s α = 0.92). The concurrent validity
was strong compared to SOBQ (r = − 0.66) and moderate compared to 6MWT (r = 0.43). Intraclass correlation
coefficients (ICC = 0.91) and a Bland Altman plot demonstrated a good reliability. K-BILD was also able to
discriminate between patients with different stages of disease (p < 0.002, Δscore > 7.4) and most results were
comparable in patients with different time since diagnosis.
Conclusion: K-BILD is a valid and reliable instrument in patients with IPF and in patients with different time since
diagnosis. To a major extent, K-BILD scores reflected the impact of dyspnoea on HRQL and the impact of physical
functional capacity measured by the 6MWT to a moderate degree. Compared to PFTs alone, K-BILD provides
additional information on the burden of living with IPF, and importantly, K-BILD is simple to implement in both
research and clinical contexts.
Trial registration: Clinicaltrials.org (NCT02818712) on 30 June 2016.
Keywords: Idiopathic pulmonary fibrosis, IPF, Health-related quality of life, Quality of life, The King’s Brief Interstitial
Lung Disease questionnaire, K-BILD, The St. Georges respiratory questionnaire, 6-min walk test, 6MWT, Danish
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive, fi-
brotic interstitial lung disease (ILD) with short life ex-
pectancy [1]. As the disease progresses, health-related
quality of life (HRQL) deteriorates due to dyspnoea, de-
creased exercise capacity, loss of mental well-being and
social isolation [2]. To address this issue, disease-specific
HRQL questionnaires focusing on the main symptoms
and life conditions in patients with IPF are warranted.
HRQL in patients with IPF has often been measured
using St. George’s Respiratory Questionnaire (SGRQ), a
disease-specific instrument developed for chronic ob-
structive lung disease (COPD) and asthma [3, 4]. How-
ever, ILD-specific HRQL questionnaires have been
developed, including the King’s Brief Interstitial Lung
Disease questionnaire (K-BILD) [5]. K-BILD is developed
and validated for measuring HRQL in a broad range of
ILDs [5]. The 15-item K-BILD is easy to complete and
considerably shorter than the 50-item SGRQ. In
addition, K-BILD has a stronger correlation to pulmon-
ary function tests (PFTs) than SGRQ [5].
K-BILD has been validated in patients with a number
of different ILDs. However, no studies have validated K-
BILD in a large cohort of patients with IPF [5, 6]. As IPF
carries the worst prognosis among ILDs, validation of K-
BILD is of great importance in this group of patients.
Also, the correlation of quality of life to time since IPF
diagnosis has not been reported in other K-BILD studies
[5, 6], and the validity of K-BILD in incident compared
to prevalent patients is yet uncovered.
Dyspnoea is a central symptom in IPF limiting many daily
activities. Thus, dyspnoea is a major determinant of HRQL
[7]. To our knowledge, the ability of K-BILD to reflect the
impact of dyspnoea on HRQL according to patients with IPF
has not been examined; however, it constitutes an important
aspect of validity that warrants further investigation.
The 6-min walk test (6MWT) is widely used to evalu-
ate the physical performance of patients with IPF. The
test provides valuable information on functional capacity
which is not obtained by PFTs, and distance walked dur-
ing the 6MWT (6MWD) correlates to HRQL [8]. How-
ever, the relationship between K-BILD and 6MWD has
not been determined in previously published studies.
K-BILD has only been translated from English into a
few other languages [6, 9]. Currently, there is no disease-
specific HRQL questionnaire for patients with IPF or
other ILDs in Danish. When translated into other lan-
guages, international use of validated, disease-specific
HRQL instruments in clinical trials and daily clinical
practice is promoted and will increase awareness of the
burdens related to living with IPF. Furthermore, focus
on HRQL can promote discussions of palliation at an
early stage of IPF, as proposed by the World Health
Organization (WHO) [10, 11].
The aim of this study was to validate K-BILD in the,
to date, largest cohort of patients with IPF, translate K-
BILD into Danish and assess how K-BILD correlates to
dyspnoea and 6MWD.
Methods
Translation and cultural adaptation
K-BILD was translated into Danish using a multistep
forward-backward translation procedure (see Add-
itional file 1) [12, 13]. Subsequently, semi-structured in-
terviews with a focus group of patients were completed
to assess the translated version of K-BILD in the target
population. During the process, the Danish versions of
K-BILD were reviewed by the developers.
Design
Consecutive patients with IPF were recruited at their out-
patient visits at the three Danish tertiary ILD centres at
the university hospitals in Aarhus, Odense and Gentofte
(Copenhagen). Both incident and prevalent patients were
included to increase the generalisability of the results. Pa-
tients aged > 18 years with a guideline-based diagnosis of
IPF were eligible for inclusion [14, 15]. Patients were ex-
cluded, if they were unable to complete the questionnaires
due to linguistic or cognitive barriers. A study on the IPF-
specific version of SGRQ (SGRQ-I) has been based on the
same cohort of patients with IPF [16].
At baseline, the patients completed K-BILD, SGRQ-I,
University of California, San Diego Shortness of Breath
Questionnaire (SOBQ) and Short Form-36 (SF-36); after
14 days, K-BILD and Global Rating of Change Scales
(GRCS) were completed. Questionnaires containing
more than 15% missing answers or lacking total or do-
main scores were excluded from the analyses. At base-
line, PFTs (forced vital capacity (FVC) and diffusion
capacity of the lung for carbon monoxide (DLCO)) and
6MWT were performed, and gender, age and physiology
index (GAP index) was determined [17].
The study was approved by the Central Denmark Re-
gion Committee on Health Research Ethics (case no. 1–
10–72-87-16) and the Danish Data Protection Agency,
and it was registered at clinicaltrials.org (NCT02818712).
The participants gave written and informed consent be-
fore participating in the study.
HRQL questionnaires
K-BILD is a 15-item self-completed questionnaire meas-
uring HRQL in patients with ILDs [5]. Responses are re-
corded on a 7-point Likert scale and results in a total
score and three domain scores: Psychological, Breath-
lessness and activities and Chest symptoms. Scores are
weighted (logit transformation) and range from 0 to 100,
with higher scores indicating better HRQL.
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SGRQ-I consists of 34 self-completed items assessing
HRQL. It was developed as a IPF-specific version of
SGRQ and has recently been further validated [16, 18].
Response options vary between several scales. Scores
range from 0 to 100 in a total score and three domain
scores: Impacts, Activity and Symptoms, higher scores
indicate impaired HRQL.
SOBQ is a 24-item self-completed questionnaire esti-
mating dyspnoea associated with activities of daily living
[19]. Patients score their symptoms on a 6-point scale,
and scores range from 0 to 120, higher scores indicate
more dyspnoea.
SF-36 is a generic quality of life questionnaire [20]. It
contains 36 self-completed items on a 3–6-point Likert
scale, assessing varying aspects of quality of life. Scores
range from 0 to 100 and result in eight domain scores
and two component scores, higher scores indicate better
quality of life.
GRCS are self-completed questionnaires designed to
assess changes from baseline to the current state of the
patients [21]. SGRQ-I was validated in the same cohort
of patients, and the items of the domains differ slightly
between the two instruments. Therefore, five GRCS were
designed for this study; four for the domains of K-BILD
(two for breathlessness and activities domain; combined
in the analyses) and one for overall HRQL (see Add-
itional file 2 for an English version). Responses are rated
on a 11-point Likert scale with numbers ranging from −
5 to 5 and corresponding answers ranging from” Very
much worse” over” Unchanged” to” Very much better”.
The questionnaires used in the study were validated in
Danish language.
Validation
Internal consistency was evaluated by calculating the
interrelatedness of the items in the questionnaire. Con-
current validity was evaluated by measuring the correla-
tions of K-BILD to SGRQ-I, SOBQ, SF-36, PFTs and
6MWD. Test-retest reliability was evaluated by compar-
ing K-BILD scores at baseline and at 14 days in stable
patients. In order to assess the validity of K-BILD in pa-
tients with different time since diagnosis, the patients
were divided into three subgroups to evaluate the pre-
ceding measures. Furthermore, known groups validity
was evaluated by estimating the ability of K-BILD to dis-
tinguish between groups of patients at different stages of
the disease. The patients were stratified into “known
groups” according to their PFTs (quartiles of FVC and
DLCO), 6MWD, use of long-term oxygen therapy
(LTOT) and GAP index.
Statistical analysis
Patients were divided into three subgroups according to
the time since diagnosis (TSD): < 1 month, 1–12months
and > 12 months; receiving antifibrotic treatment or not
(AFT) and centre of inclusion (CEI).
The characteristics of patients completing or not
completing the questionnaires (responders and non-
responders) at baseline and after 14 days were
compared using Fisher’s exact test for binomial
data. Continuous, normally distributed data were
analysed using independent two-sample t-test.
Otherwise, the Wilcoxon-Mann-Whitney test was
used. Normality was assessed by quantile-quantile
plots (QQ-plots) and variance homogeneity was
accessed using the F-test.
Internal consistency was assessed for K-BILD by calcu-
lating Cronbach’s α for each domain and total score;
values > 0.7 indicate a reliable internal consistency [22].
Concurrent validity was measured using Pearson’s cor-
relation coefficients, after evaluation of linearity and nor-
mality was performed. Correlation coefficients close to
0.7 are considered as strong, close to 0.5 as moderate
and close to 0.3 as weak.
Intraclass correlation coefficients (ICC) and Bland-
Altman plots were used to examine test-retest reliability.
Normality was assessed by QQ-plots. Patients were cate-
gorised as stable if they scored − 1 to 1 in GRCS after
14 days. ICC values > 0.7 are considered acceptable mea-
sures of reliability [22].
If K-BILD total scores in the known groups followed a
normal distribution, the independent two-sample t-test
was used for comparison, and otherwise the Wilcoxon-
Mann-Whitney test was used. Multiple linear regression
analysis was used for comparison of GAP groups. Nor-
mality was assessed by QQ-plots, variance homogeneity
was accessed using the F-test and the multiple linear re-
gression model was checked by diagnostic plots of the
residuals. Effect sizes were calculated from analysis of
variance (ANOVA) or multiple linear regression and
were reported as partial η2: small effect 0.01, medium ef-
fect 0.06 and large effect 0.14 [23]. ANOVA was checked
by diagnostic plots of the residuals and Bartlett’s test for
equal variances. Data were analysed using STATA, ver-
sion 14.
Results
Translation and cultural adaptation
Permission to translate K-BILD was obtained from the
developers of the questionnaire [5]. After the forward-
backward translation procedure, the Danish version of
K-BILD was approved by the developers. Semi-
structured interviews were conducted in a representative
group of five patients with IPF after completing the Da-
nish version of K-BILD. The developers of K-BILD ac-
cepted a minor adjustment after the interviews. The
final Danish version of K-BILD can be found in
Additional file 3.
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Psychometric validation
A total of 150 patients with IPF were recruited from the
three tertiary interstitial lung diseases centres in
Denmark (110 patients in Aarhus, 24 in Gentofte and 16
in Odense) between August 2016 and March 2018.
Demographics of participants are presented in Table 1.
At baseline, the number of questionnaires with more
than 15% missing answers, missing domain or total score
was: K-BILD 1 (0.7%); SGRQ-I 2 (1.3%); SOBQ 3 (2.0%)
and SF-36 1 (0.7%). Eleven patients did not return the
questionnaires by mail at 14 days (7.3%). Missing data
analyses demonstrated no differences between re-
sponders and non-responders, except for the 6MWD
where responders at 14 days walked 102.9 m longer on
average than non-responders (Additional file 4).
Internal consistency
Cronbach’s α was high in K-BILD, especially in the psy-
chological domain, the breathlessness and activities do-
main, and the total score (Table 2). The results of the
total score, psychological domain and breathlessness and
activities domain were comparable in the TSD, AFT and
CEI subgroups (data not shown). Only the results from
the chest domain deviated among patients with an IPF
diagnosis > 12months (0.53), patients on antifibrotic
treatment (0.61) and patients from Gentofte (0.67) and
Odense (0.45).
Concurrent validity
K-BILD total and domain scores had moderate to strong
correlations to SGRQ-I total and domain scores as well
as to SOBQ score. Correlations to SF-36 summary do-
main scores, PFTs and 6MWD were strong to weak
(Table 3). Most correlations were similar for the TSD,
AFT and CEI subgroups (data not shown). Exceptions
were the weaker correlations between SF-36 MCS and
both K-BILD total score and psychological domain in
patients with an IPF diagnosis < 1 month (0.37 and 0.29,
respectively). Correlations between 6MWD and K-BILD
total score and psychological domain became stronger
with increasing time since diagnosis (total score: 0.20 to
0.64, psychological domain: 0.13 to 0.46). In patients
from Gentofte, K-BILD psychological correlated stronger
to SF-36 PCS (0.66) and weaker to SF-36 MCS (0.35).
The correlations across most anchors were weaker in
the K-BILD psychological domain in patients from
Odense (− 0.04 to 0.77).
Test-retest reliability
After 14 days, most patients were rated stable as evalu-
ated by GRCS in both overall health status and in the
three domains of K-BILD (Table 4). In these patients, K-
BILD had high ICC values (Table 4). A Bland-Altman
plot showed good agreement between the answers at
baseline and after 14 days (Fig. 1). Results were compar-
able for all TSD, AFT and CEI subgroups (data not
shown), except for a slight deviation in the chest domain
among patients from Gentofte (0.67).
Known groups validity
Patients in the upper quartiles of 6MWD, FVC % pre-
dicted and DLCO % predicted had significantly higher
K-BILD total scores than patients in the lower quartiles.
Patients receiving LTOT scored significantly lower in K-
BILD total score than patients without oxygen therapy.
Increasing disease severity according to the GAP index
resulted in significantly decreasing K-BILD scores. These
findings were supported by strong effect sizes, especially
Table 1 Demographics of the participants at inclusion (n = 150)
Characteristics Value
Male (%) 122 (81.3%)
Age, years ± SD 72.9 ± 6.2
Time since diagnosis, years (range) 0.5 (0.0–9.3)
Smoking status
Current (%) 9 (6.0%)
Former (%) 101 (67.3%)
Never (%) 40 (26.6%)
Long-term oxygen therapy (%) 19 (12.7%)
Antifibrotic treatment 85 (56.7%)
FVC, % predicted ± SD 87.2 ± 23.1
DLCO, % predicted ± SD 48.4 ± 14.1
6MWD, m ± SD 450.3 ± 112.5
K-BILD total ± SD 58.3 ± 12.4
SGRQ-I total ± SD 42.9 ± 22.3
SOBQ ± SD 34.6 ± 25.3
SF-36 PCS ± SD 42.5 ± 8.7
SF-36 MCS ± SD 50.1 ± 10.5
Values are presented as n (%), mean ± standard deviation (SD) or median with
range [16]. FVC Forced vital capacity, DLCO Diffusion capacity of the lung for
carbon monoxide, 6MWD Distance walked during the 6-min walk test, K-BILD
King’s Brief Interstitial Lung Disease questionnaire, SGRQ-I IPF-specific version
of St. George’s Respiratory Questionnaire, SOBQ University of California, San
Diego Shortness of Breath Questionnaire, SF-36 Short Form-36, PCS Physical
Component Score, MCS Mental Component Score




Breathlessness and activities 0.84
Chest symptoms 0.71
Data represent Cronbach’s α for all patients. K-BILD King’s Brief Interstitial Lung
Disease questionnaire
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for 6MWD and DLCO, but also for FVC and GAP index
(Fig. 2 and Additional file 5).
Discussion
The current work describes how K-BILD was translated
into Danish and validated in the largest cohort of pa-
tients with IPF to date. During the translation and cul-
tural adaptation, only minor adjustments were required.
The questionnaire was easy to complete for the patients,
was shown to be a comprehensive and relevant measure
of HRQL and performed well in a non-English speaking
population. K-BILD had high internal consistency, mod-
erate to strong concurrent validity, good test-retest reli-
ability, high validity across patients with different time
since diagnosis and high discriminative ability in known
groups.
This study was conducted among the largest number
of patients from a single country included in a transla-
tion and validation study of K-BILD. In a previous Ger-
man study, K-BILD was only translated, but not
validated in German [9]. Another validation study in-
cluded 176 patients, but these were distributed across
four countries, with 96 Dutch patients in the largest sub-
group [6]. In a larger cohort, results become more valid
as this allows for a wider variation in disease severity,
views on life and socio-economic backgrounds, provid-
ing a better reflection of the patient population.
Additionally, our study included the largest number of
measures to evaluate concurrent validity to date, includ-
ing SOBQ and 6MWD. Even though dyspnoea is a
major symptom of IPF and one of the most important
factors affecting HRQL [7], no previous studies have
compared K-BILD to any specific measures of dyspnoea.
SOBQ is a dyspnoea-specific instrument validated for
use in IPF [24, 25]. Moderate to strong correlations to
SOBQ demonstrate that K-BILD provides a good reflec-
tion of this central symptom and indicator of HRQL in
IPF. This adds to the validity of K-BILD that can be ap-
plied without an additional measure of dyspnoea in a
clinical or research setting. Concurrent validity of K-
BILD compared to SGRQ-I and SF-36 was moderate to
strong. Overall, K-BILD correlated better to other
disease-specific questionnaires than to the generic SF-36,
which underlines the importance of disease-specific
instruments.
6MWD is a functional measure of exercise capacity
and decreasing walking distance during the test is associ-
ated with declining HRQL [8]. However, no other stud-
ies have assessed the relationship between K-BILD and
6MWD. Correlations to 6MWD were moderate to weak
with the strongest observations to K-BILD total score
and the breathlessness and activity domain. Likewise,
correlations to FVC % predicted and DLCO % predicted
were moderate to weak. Similar correlations have been
reported for other HRQL questionnaires such as A Tool
to Assess Quality of life in IPF (ATAQ-IPF), SGRQ and
SGRQ-I [3, 18, 26]. This emphasizes that physiological
measures of disease severity do not reflect the entire im-
pact of living with IPF. HRQL measures contribute with
information about unique aspects of the consequences
of the disease that are not otherwise registered and add
important information that is not achieved alone by
physiological measures of disease severity.
The ability of the instrument to distinguish between pa-
tients with different disease severity is also an aspect of valid-
ity. K-BILD clearly distinguished patients when grouped into
the highest and lowest quartiles of 6MWD, pulmonary func-
tion, by GAP index and by using or not using LTOT. Our
study is the first to describe this aspect of validity in K-BILD
using the 6MWD and GAP index. The discriminative ability
of K-BILD in terms of pulmonary function and LTOT has
only been reported in one previous study [6].
Internal consistency of K-BILD was good in the chest
domain and high in the total score and the two other

















K-BILD total − 0.76 − 0.70 − 0.71 − 0.58 − 0.66 0.58 0.56 0.30 0.45 0.43
K-BILD psychological −0.58 − 0.55 − 0.52 − 0.47 −0.45 0.33 0.60 0.24 0.34 0.31
K-BILD breathlessness and
activities
−0.78 − 0.70 −0.76 − 0.57 −0.76 0.69 0.45 0.34 0.50 0.54
K-BILD chest symptoms −0.69 − 0.66 −0.54 − 0.64 −0.57 0.54 0.44 0.24 0.32 0.30
All data are presented as Pearson’s correlation coefficients for all patients. All correlations had a p-value < 0.01 [16]. K-BILD King’s Brief Interstitial Lung Disease
questionnaire, SGRQ-I IPF-specific version of St. George’s Respiratory Questionnaire, SOBQ University of California, San Diego Shortness of Breath Questionnaire, SF-
36 Short Form-36, PCS Physical Component Score, MCS Mental Component Score, FVC Forced vital capacity, DLCO diffusion capacity of the lung for carbon
monoxide, 6MWD Distance walked during the 6-min walk test
Table 4 Test-retest reliability of K-BILD
K-BILD n ICC
Total 103 (74.1%) 0.89
Psychological 109 (78.4%) 0.80
Breathlessness and activities 113 (81.3%) 0.89
Chest symptoms 105 (75.5%) 0.76
Data are presented as number of stable patients (% of responders, no. 139)
and intraclass correlation coefficients (ICC). K-BILD King’s Brief Interstitial Lung
Disease questionnaire
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domains. This indicates a considerable interrelatedness
of the items in the questionnaire, meaning that ques-
tions measuring the same construct have similar scores.
Test-retest reliability was high in K-BILD, confirming
that the questionnaire had a good repeatability. Overall,
the Danish version of K-BILD performed comparable to
the original and translated versions [5, 6].
Even though K-BILD has been developed for use in
patients with various ILDs, IPF is the most severe dis-
ease with the poorest prognosis. Therefore, validation of
K-BILD in patients with IPF is highly important to have
a valid instrument to measure HRQL in these patients.
Our study has demonstrated that K-BILD is able to re-
flect the impact on HRQL in patients living with this
crippling disease. Increased knowledge about HRQL in
patients with IPF may be used to discuss and improve
the most cumbersome issues of the disease in daily clin-
ical care. It may also facilitate discussions of palliation as
recommended by the WHO at an early stage in progres-
sive diseases [10, 11].
To our knowledge, the validity of K-BILD across pa-
tients with different time since diagnosis was evaluated
in this study for the first time. As patients with IPF often
have respiratory symptoms for a long time before the
diagnosis of IPF, the exact disease duration is unknown
[27]. Therefore, time since diagnosis was chosen as an
average proxy for disease duration. K-BILD proved to be
equally valid across several subgroups, increasing the
validity and possible application of the instrument to
any patient with IPF. However, the chest domain should
be interpreted with caution in patients having the diag-
nosis for more than 12months, as the internal
consistency was moderate for this group. It is possible
that the chest symptoms of chest tightness, air hunger
and wheezing may change and become less consistent
with increasing duration of the disease. The increasing
correlations to 6MWD indicate that physical functional
capacity has a growing impact on HRQL as the disease
advances. The weaker association to SF-36 MCS in inci-
dent patients may be incidental or due to a recent ser-
ious and life-changing diagnosis, which may influence
the general mental health status of SF-36 more than the
disease-specific domains of K-BILD. The differing results
in patients from Gentofte and Odense may partly be ex-
plained by the small sample sizes.
Analyses for missing data showed no significant differ-
ences between responders and non-responders in terms
of demographics, medical treatment, long-term oxygen
therapy or PFTs. The only statistically significant differ-
ence was a shorter 6MWD in non-responders compared
to responders after 14 days. The results were considered
reliable for the entire group of patients, as no significant
bias was thought to be introduced due to missing
answers.
Compared to other HRQL questionnaires, K-BILD is
short with only 15 items and is easy to complete. In
comparison, SGRQ consists of 50 items and SGRQ-I
contains 34 items [4, 18]. Another IPF-specific HRQL
questionnaire is ATAQ-IPF containing 74 items [26].
Despite the shortness of K-BILD, it has the same validity
Fig. 1 Bland-Altman plot of the repeatability of K-BILD in all responding stable patients. The solid line represents the mean difference, and the
dashed lines represent the 95% limits of agreement. K-BILD: King’s Brief Interstitial Lung Disease questionnaire
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as SGRQ, SGRQ-I and ATAQ-IPF in terms of internal
consistency, concurrent validity, test-retest reliability and
known groups validity [3, 5, 6, 18, 26]. Another short
HRQL measure is the COPD Assessment Test (CAT),
which has also been validated in both IPF and other
ILDs [28–30]. A short HRQL questionnaire is advanta-
geous in both clinical and research settings for both pa-
tients and health care professionals.
As K-BILD has been developed for use in different
ILDs, the lack of patients with other ILDs than IPF is a
limitation to the Danish version of K-BILD. However,
other studies including other ILDs have shown a com-
parable validity of K-BILD in patients with IPF and pa-
tients with other ILDs [5, 6] and it can therefore be
assumed that the Danish version of K-BILD will be
equally valid in patients with other ILDs. Patients in-
cluded in the study had relatively well-preserved FVC%
and moderately impaired DLCO%. Patients with similar
lung function and HRQL have been reported in IPF
registries [31, 32]. Preservation of lung function may be
due to earlier diagnosis of IPF. Responsiveness and min-
imal important difference (MID) were not assessed in
this study. Patel et al. have reported a MID of 8 unit
change (range 6–10) for K-BILD, but the study included
only 57 patients, and a larger study of MID is thus
needed [33]. The present cohort of patients with IPF
participates in a longitudinal study that will evaluate
both responsiveness and MID for K-BILD. One of the
strengths of our study is the inclusion of the large cohort
of patients with IPF with different time since diagnosis.
The width of the cohort increases the generalisability of
the results to IPF cohorts. Also, the study included new
measures of dyspnoea and functional physical capacity
that have not been compared to K-BILD before, thus
expanding the current knowledge on validity and applic-
ability of K-BILD.
Fig. 2 K-BILD total score in (a) the lower and upper quartile of 6MWD at baseline, b the lower and upper quartile of FVC % predicted at baseline,
c the lower and upper quartile of DLCO % predicted at baseline, d use of long-term oxygen therapy and e GAP index. The midlines of the boxes
indicate the median values and the boundaries illustrate the 25th and 75th percentiles; the whiskers are the upper (1.5 interquartile range above
75th percentile) and lower adjacent values (1.5 interquartile range below 25th percentile). The dots are outlying values. 6MWD: Distance walked
during the 6-min walk test; K-BILD: King’s Brief Interstitial Lung Disease questionnaire. FVC: Forced vital capacity; DLCO: diffusion capacity of the
lung for carbon monoxide; LTOT: Long-term oxygen therapy; GAP: Gender, age, physiology. ES: Effect size (partial η2)
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Conclusions
In conclusion, K-BILD is a valid and reliable instrument
to use in patients with IPF and can be applied in patients
with different time since diagnosis. The Danish version is
as valid and reliable as the original. To a major extent, K-
BILD scores reflect the impact of dyspnoea on HRQL and
the impact of physical functional capacity measured by
6MWD to a moderate degree. Compared to PFTs alone,
K-BILD provides additional information on the burden of
living with IPF, and importantly, K-BILD is simple to im-
plement in both research and clinical contexts.
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